Search

In a context where these innovations are advancing rapidly, Spain needs to modernize programs and instruments that enable harnessing our scientific and technological potential, transforming it into

We spoke with Ana Isabel Jiménez, General Director of Sylentis, to learn how mRNA technology already provides alternative pathways that allow targeting key proteins involved in the development of

To explore Oryzon’s clinical candidate ORY-4001 in ALS. The ALS Association to provide 500,000 USD funding.

The company is developing a proprietary platform technology to design new drugs targeting protein allosteric sites to treat cancer and potentially many other diseases.

All biobanks in the RVB currently have a quality management system certified according to the ISO 9001:2015.

The CrisBio® platform uses a totally different protein expression system, since it uses the pupae of the Trichoplusia NI moth as natural bioreactors for the production of enzymes and recombinant

Meet BioClonal, our new member. We talked to its with Paula Garfella Founder & CEO and Jessika Valero, CRO.

ZETA is committed to making a positive contribution by delivering innovative and sustainable strategies that help our customers achieve their Net Zero goals.

GENESIS Biomed inaugurated its new site at Valencia last week at the BioHub VLC, as part of the GENESIS Biomed Annual Conference in the Valencian Community.

The purpose behind our request for the creation of the High Commissioner is to strengthen Spain's commitment to deep technologies at a critical moment for Europe's strategic autonomy.

Funding provided by Nice & Green SA, a Swiss private investor.